Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
azithromycin sustained release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| azithromycin sustained release | DRUG | azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose |
| placebo | OTHER | placebo |
| levofloxacin | DRUG | 500 mg (two 250 mg capsules) by mouth once daily for 7 days |
Inclusion Criteria: Patients with clinical evidence of mild to moderate community-acquired pneumonia, including cough productive of sputum and a diagnosis of pneumonia, were included. Exclusion Criteria: Key exclusion criteria were treatment with any systemic antibiotic of greater than one dose o...
Top 4 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus |
| Agenus Inc. | AGEN | 1 | PHASE2 | agenT-797 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | V175, V175A |
Azithromycin sustained release is an investigational formulation of the antibiotic azithromycin developed by Pfizer, Inc. (ticker: PFE). It is a small molecule being studied for the treatment of pneumonia. The sustained-release design is intended to deliver the drug over an extended period, though the specific pharmacokinetic properties are not detailed here.
Azithromycin sustained release is being developed for the treatment of pneumonia. It is intended for adults with mild to moderate pneumonia, as studied in a Phase 3 clinical trial. The drug has not been approved for any indication and remains investigational.
Azithromycin sustained release is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the sponsor of the clinical trial evaluating this formulation.
Azithromycin sustained release is in Phase 3 clinical development. A single Phase 3 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Azithromycin sustained release has been evaluated in one completed Phase 3 trial, NCT00643734. This multicenter, randomized, double-blind, double-dummy study compared azithromycin sustained release with levofloxacin for the treatment of mild to moderate pneumonia in adults. The trial enrolled 468 patients across the United States, Canada, Chile, India, Lithuania, Mexico, Peru, and Russia.